Article
Immunology
Sofia Batalha, Catarina Monteiro Gomes, Catarina Brito
Summary: This study presents a unique human 3D model for studying the immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Eva Villar-Alvarez, Irene Golan-Cancela, Alberto Pardo, Brenda Velasco, Javier Fernandez-Vega, Adriana Cambon, Abeer Al-Modlej, Antonio Topete, Silvia Barbosa, Jose A. Costoya, Pablo Taboada
Summary: A multimodal theranostic nanoplatform targeting both HER2 and HER3 was developed to increase patient survival in breast cancers. In vitro assays showed effective HER3 silencing and HER2 inhibition, along with a decrease of Akt protein kinase. In vivo studies in a tumor-bearing mice model demonstrated a significant decrease of tumor volume after nanoparticle administration and NIR light irradiation, confirming the potential efficacy of the hybrid nanocarrier.
Article
Multidisciplinary Sciences
Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yanez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung
Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Article
Chemistry, Multidisciplinary
Ting Yu, Wen Nie, Zehua Hong, Yihong He, Jing Chen, Xue Mi, Shuping Yang, Xiaoling Li, Bilan Wang, Yunzhu Lin, Xiang Gao
Summary: By utilizing the RGD-DMA/pCCL19-BMS-1 system, significant inhibition of tumor progression was achieved, along with induction of locally high concentrations of immunostimulatory cytokines at tumor sites, effectively reshaping the immunosuppressive TME.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Article
Oncology
Ezgi Tulukcuoglu Guneri, Emile Lakis, Ismail Hajji, Elian Martin, Jerome Champ, Aurore Rampanou, Jean-Yves Pierga, Jean-Louis Viovy, Charlotte Proudhon, Francois-Clement Bidard, Stephanie Descroix
Summary: Among different biomarkers, circulating tumor cells have shown particular interest in breast cancer. This study proposes a new approach to characterize CTCs by integrating proximity ligation assay on a chip, allowing the quantification of HER2-HER3 dimerization event. This method can improve the understanding of breast cancer mechanism and patient management.
Article
Pharmacology & Pharmacy
Barbara Buccinna, Cristina Ramondetti, Marco Piccinini
Summary: In this study, the effects of lapatinib alone and in combination with AMPK activator GSK-621 were evaluated in HER2-overexpressing breast cancer cells. The results show that the combination of these two drugs can reduce lapatinib-mediated HER3 upregulation and prevent reactivation of AKT and ERK1/2 kinases. The combination treatment synergistically decreases cell viability and greatly reduces the ability of NRG to rescue cell proliferation. Additionally, it hampers the establishment of a transcriptionally permissive chromatin structure at the HER3 promoter.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Oncology
Paolo Nuciforo, John Townend, Martine J. Piccart, Shona Fielding, Panagiota Gkolfi, Sarra El-Abed, Evandro de Azambuja, Gustavo Werutsky, Judith Bliss, Volker Moebus, Marco Colleoni, Alvaro Moreno Aspitia, Henry Gomez, Andrea Gombos, Maria A. Coccia-Portugal, Ling-Ming Tseng, Georg Kunz, Guillermo Lerzo, Joohyuk Sohn, Vladimir Semiglazov, Cristina Saura, Judith Kroep, Antonella Ferro, David Cameron, Richard Gelber, Jens Huober, Serena Di Cosimo
Summary: Dual anti-HER2-targeted therapy combined with chemotherapy significantly improves the rate of pathological complete response (pCR) in breast cancer patients. However, limited data exist on the long-term impact of the increased pCR on survival.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Meng He, Zi-Fan Chen, Li Zhang, Xiangyu Gao, Xiaoyi Chong, Hao-shen Li, Lin Shen, Jiafu Ji, Xiaotian Zhang, Bin Dong, Zi-Yu Li, Tang Lei
Summary: This study aimed to assess the correlation between CT-derived body composition parameters and SII and OS in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. The study found that high SII and high SFA were associated with OS, while sarcopenia was not an independent prognostic factor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Mohammad Hossein Kazemi, Alireza Najafi, Jafar Karami, Foad Ghazizadeh, Hassan Yousefi, Reza Falak, Elahe Safari
Summary: Recent advancements in cancer immunotherapy, particularly immune checkpoint (IC) blockers, have shown promising results in clinical settings. Immunometabolism plays a crucial role in regulating immune responses, and dual targeting of ICs and metabolic pathways may help restore immune cells' antitumor activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Shoichiro Ohtani, Tomomi Fujisawa, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi Sakurai, Hideo Shigematsu, Katsumasa Kuroi, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi
Summary: The Neo-LaTH study found that the duration of neoadjuvant therapy and the addition of endocrine therapy did not affect the response in HER2-positive breast cancer patients. Patients achieving a pathological complete response (CpCR) plus ypN0 after neoadjuvant treatment had better 5-year survival outcomes, regardless of adjuvant anthracycline therapy. Favorable survival outcomes were observed in patients with small size and clinically node-negative tumors.
Article
Agriculture, Dairy & Animal Science
Edoardo Collarini, Marika Gioia, Giada Cordoni, Ivan Norscia
Summary: This study examines the applicability of the domestication syndrome in domestic pigs and wild boar hybrids. The findings suggest that domestic pigs engage in more social play, but also display more aggression compared to wild boar hybrids. The domestication syndrome does not fully apply to social play or aggression, possibly due to artificial selection for tameness towards humans.
Article
Chemistry, Multidisciplinary
Yuanji Feng, Jiayan Wu, Jie Chen, Lin Lin, Sijia Zhang, Zhiyu Yang, Pingjie Sun, Yanhui Li, Huayu Tian, Xuesi Chen
Summary: This study developed a revolutionary dual gene delivery system loading pshVEGF-A and pshPD-L1 to overcome adaptive resistance to ICB therapy, achieving effective anti-tumor immunotherapy. The strategy eliminates adaptive resistance, achieves tumor vessel normalization, and reprograms the tumor immune microenvironment, contributing to the diversity of immune combination therapy.
Article
Medicine, Research & Experimental
T. C. Stevenson Keller, Lillian Lim, Swapnil Shewale, Kendra McDaid, Ingrid Marti-Pamies, Alan T. Tang, Carl Wittig, Andrea A. Guerrero, Stephanie Sterling, N. Adrian Leu, Marielle Scherrer-Crosbie, Phyllis A. Gimotty, Mark L. Kahn
Summary: Recent studies have shown that promoting lymphatic growth post-MI does not significantly improve cardiac function, refuting the contribution of lymphangiogenesis to heart function and suggesting that the effect of exogenous VEGF-C is likely mediated by nonlymphangiogenic mechanisms.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Pharmacology & Pharmacy
Supusson Pengnam, Praneet Opanasopit, Theerasak Rojanarata, Boon-ek Yingyongnarongkul, Chopaka Thongbamrer, Samarwadee Plianwong
Summary: The challenge in HER2-overexpressing breast cancer therapy is to develop an effective target therapy. This study formulated lipid-based nanoparticles for delivering siRNA into HER2-overexpressing breast cancer cells. The dual-targeted therapy using Mcl-1 siRNA nioplex and trastuzumab showed synergistic effects in inhibiting cell growth and inducing apoptosis.
Article
Immunology
Carmen Mestre-Duran, Carla Martin-Cortazar, Blanca Garcia-Solis, Alicia Pernas, Lidia Pertinez, Victor Galan, Luisa Sisinni, Laura Clares-Villa, Alfonso Navarro-Zapata, Karima Al-Akioui, Adela Escudero, Cristina Ferreras, Antonio Perez-Martinez
Summary: Natural killer (NK) cells, as part of the innate immune system, play a vital role in defending against infected and transformed cells. The balance between inhibitory and activating receptors on NK cells controls their cytotoxic capability. The JAK/STAT pathway and Toll-like receptors (TLRs) are key factors in NK cell activation and response to pathogens. Ruxolitinib, a JAK1/2 inhibitor, has shown moderate effects on TLR pathway activation and cytokine production in NK cells.
FRONTIERS IN IMMUNOLOGY
(2023)